Skip to content
Screener

Bicara Therapeutics BCAX Q1 2026 earnings

Reported May 11, 2026 · Before market open

EPS-$0.93Miss by $0.29
EPS estimate-$0.64

Next report

Aug 11, 2026 (Tomorrow)
EPS estimate-$0.82

Financials

Q1 2026

Income statement

See full
Operating income-$60.2M-44.2%
Net income-$56.2M-52.6%
EPS (diluted)-$0.93-36.8%

Balance sheet

See full
Cash & equivalents$323.5M-30.0%
Total debt$1.4M+144%
Total equity$514.0M+12.0%
Total assets$553.6M+15.8%

Cash flow

See full
Operating cash flow-$37.5M-33.5%
CapEx$60.0K—
Free cash flow-$37.6M-33.7%

Valuation & ratios

Valuation

as of 08/07/26
See full
Market cap$1.81B+217%
Enterprise value$1.49B+1,000%

Returns & leverage

See full
Return on equity-32.3%—
Debt / equity0×0.0×
Current ratio13.9×-10.8×

FAQ

When did Bicara Therapeutics report Q1 2026 earnings?
Bicara Therapeutics (BCAX) reported Q1 2026 earnings on May 11, 2026 before market open.
What were Bicara Therapeutics's Q1 2026 revenue and EPS?
Bicara Therapeutics reported eps of $-0.93 for Q1 2026.
Did Bicara Therapeutics beat estimates in Q1 2026?
EPS missed the consensus estimate of $-0.64 by $0.29.
How did Bicara Therapeutics's Q1 2026 results compare year-over-year?
Compared to the same quarter a year prior, eps declined 36.8% from $-0.68.
Where can I find Bicara Therapeutics's Q1 2026 SEC filings?
You can read the 8-K earnings release (0001628280-26-033135) and the 10-Q periodic report (0001628280-26-033429) directly on SEC EDGAR. The filing index links above go to sec.gov.